When antitrust authorities have concerns, what remedies can clear a deal, and how do they affect deal certainty and timing?

Where a merger raises competition concerns, authorities can clear it subject to remedies. Structural remedies — divesting a business, brand, or assets to a suitable buyer — are preferred because they durably restore competition and are clean to monitor. Behavioral/conduct remedies — commitments on pricing, access, interoperability, supply, or firewalls — are used where a carve-out isn't feasible, but regulators distrust them as hard to monitor and enforce. Remedies affect the deal in several ways: they reduce the value/scope of what the buyer acquires (you may sell the very assets you wanted), require an acceptable divestment buyer (sometimes an 'upfront buyer' condition before clearance), and extend timing through a Phase II review and negotiation. Parties manage this with risk-allocation in the SPA — 'hell-or-high-water' or efforts standards on obtaining clearance, long-stop dates, and reverse break fees if regulators block it.